HomeMao InhibitorsMao Inhibitors + Risedronate Sodium

Does Mao Inhibitors Interact with Risedronate Sodium?

Mao Inhibitors and Risedronate Sodium have a moderate drug interaction according to U.S. FDA drug labeling data. PPIs may cause faster drug release and increase risedronate bioavailability. Concomitant administration is not recommended. The mechanism involves increased stomach ph causes faster drug release from enteric coating. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Moderate
Management
Monitor for effects
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Mao Inhibitors and Risedronate Sodium occurs because increased stomach ph causes faster drug release from enteric coating. Clinically, this means ppis may cause faster drug release and increase risedronate bioavailability. concomitant administration is not recommended. This is classified as a moderate interaction. While it may not require stopping either medication, your healthcare provider should be aware you are taking both so they can monitor for potential effects and adjust treatment if necessary.

What To Tell Your Doctor or Pharmacist

If you are taking Mao Inhibitors and your doctor is considering prescribing Risedronate Sodium (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Mao Inhibitors+💊 Risedronate Sodium(Atelvia)

Severity & Interaction Details

🟡
moderate
Be aware — moderate interaction
Documented interaction with manageable risk. May require dose adjustment or monitoring.
Severity scale
MinorContra
On record
Yes
Drug A class
Drug B class
Source
NLP:risedronate sodium

What this means in plain English

PPIs may cause faster drug release and increase risedronate bioavailability. Concomitant administration is not recommended.

What the FDA label says

"Increased stomach pH causes faster drug release from enteric coating"

📖 Source: NLP:risedronate sodium

Share this result:XFacebookWhatsAppReddit
Add more drugs
Check Mao Inhibitors and Risedronate Sodium against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.